FRACTYL HEALTH, INC. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand how Fractyl Health (ticker: GUTS) is performing. My goal is to break down their latest updates so you can decide if this "moonshot" company fits your investment goals.

1. What does this company do?

Fractyl wants to "reprogram" how the body handles metabolism. Instead of just managing obesity or type 2 diabetes with daily pills or shots, they are developing procedures and gene therapies to fix the root causes in the gut and pancreas.

Their two main projects are:

• Revita: A 45-minute outpatient procedure that uses heat to "reset" the lining of the upper intestine. By removing this lining, the procedure aims to improve how the body manages insulin and metabolism.
• Rejuva: A gene therapy platform that delivers therapeutic genes directly to the pancreas. It aims to restore the body’s natural ability to produce insulin and GLP-1, potentially offering a "functional cure" for Type 2 diabetes.

2. The "GLP-1" Pivot & Real-World Results

Fractyl is betting on the "post-GLP-1" market. They want to help people keep weight off after they stop taking drugs like Ozempic or Wegovy, which often leads to rapid weight regain.

We recently received encouraging data from a study in Germany:

• Durable Results: Patients who had the Revita procedure lost an average of 8% of their weight within three months. This weight loss lasted for up to two years.
• Better Blood Sugar: Patients saw their HbA1c levels drop by 1.0% to 1.5%. These improvements stayed stable for two years. Many patients cut their daily insulin or medication needs by at least 50%.
• Patient Satisfaction: Over 90% of participants reported high satisfaction. They preferred the "one-and-done" procedure over the lifelong commitment of daily injections.

3. Clinical Progress: The "Race Against Time"

The company is focused on the REMAIN-1 study. This is their final trial needed for FDA approval to help patients maintain weight after using GLP-1 drugs.

• Timeline: Enrollment finished in early 2025. They expect results in late 2026.
• Strategy: The FDA has provided a clear path for approval. To focus on this, the company halted the REVITALIZE-1 study for Type 2 diabetes. This move saves them roughly $15–$20 million per year.

4. Financial "Status"

Fractyl is in the early "investment" phase. They have high costs and no sales revenue.

• Cash Position: They hold about $115 million in cash.
• Burn Rate: The company spends roughly $10 million to $12 million per month.
• Survival: Management warned they may run out of money by the end of 2026. To reach their trial results, they will likely need to raise $100 million to $150 million. This will require issuing more shares, which reduces your ownership percentage.

5. The Bottom Line for Investors

Fractyl is a high-risk "moonshot." They have no products for sale in the U.S. and no revenue. While the German data is promising, the company’s finances are shaky. They must succeed in the REMAIN-1 trial by late 2026 to secure FDA approval or attract a buyer.

Decision Checklist:

• Are you comfortable with high volatility? This stock will likely swing based on trial updates.
• Can you handle dilution? Expect the company to sell more shares to fund their operations before they become profitable.
• What is your timeline? If you are looking for a quick return, the 2026 trial deadline is the primary event to watch. If the data succeeds, the company becomes a much more attractive target for acquisition by a larger pharmaceutical firm.